PDF(Pubmed)
Abstract：
UNASSIGNED: Pancreatic cancer is a highly aggressive malignancy with limited response to chemotherapy. This research aims to compare the effectiveness and safety of regional intra-arterial chemotherapy (RIAC) with conventional systemic chemotherapy in treating advanced stages of pancreatic cancer.
UNASSIGNED: A comprehensive literature review was conducted using databases such as PubMed, Embase, Web of Science, and the Cochrane Library. Studies assessing the comparative outcomes of RIAC and systemic chemotherapy were included. Data extraction and quality evaluation were performed independently by two researchers. Statistical analysis was conducted using STATA16 software, calculating odds ratios (OR), risk differences (RD), and 95% confidence intervals (CI).
UNASSIGNED: Eleven studies, comprising a total of 627 patients, were included in the meta-analysis. The findings showed that patients undergoing RIAC had significantly higher rates of partial remission (PR) compared to those receiving systemic chemotherapy (OR = 2.23, 95% CI: 1.57, 3.15, I2= 0%). Additionally, the rate of complications was lower in the RIAC group (OR = 0.45, 95% CI: 0.33, 0.63, I2= 0%). Moreover, patients treated with RIAC had notably longer median survival times.
UNASSIGNED: The results of this research indicate that RIAC is associated with a higher rate of partial remission, improved clinical benefits, and fewer complications compared to systemic chemotherapy in the management of advanced pancreatic cancer. These findings suggest that RIAC may be a more effective and safer treatment option for patients with advanced stages of pancreatic cancer.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/, identifier CRD42023404637.
UNASSIGNED: A comprehensive literature review was conducted using databases such as PubMed, Embase, Web of Science, and the Cochrane Library. Studies assessing the comparative outcomes of RIAC and systemic chemotherapy were included. Data extraction and quality evaluation were performed independently by two researchers. Statistical analysis was conducted using STATA16 software, calculating odds ratios (OR), risk differences (RD), and 95% confidence intervals (CI).
UNASSIGNED: Eleven studies, comprising a total of 627 patients, were included in the meta-analysis. The findings showed that patients undergoing RIAC had significantly higher rates of partial remission (PR) compared to those receiving systemic chemotherapy (OR = 2.23, 95% CI: 1.57, 3.15, I2= 0%). Additionally, the rate of complications was lower in the RIAC group (OR = 0.45, 95% CI: 0.33, 0.63, I2= 0%). Moreover, patients treated with RIAC had notably longer median survival times.
UNASSIGNED: The results of this research indicate that RIAC is associated with a higher rate of partial remission, improved clinical benefits, and fewer complications compared to systemic chemotherapy in the management of advanced pancreatic cancer. These findings suggest that RIAC may be a more effective and safer treatment option for patients with advanced stages of pancreatic cancer.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/, identifier CRD42023404637.
摘要：
■胰腺癌是一种对化疗反应有限的高度侵袭性恶性肿瘤。这项研究旨在比较区域性动脉内化疗（RIAC）与常规全身化疗治疗晚期胰腺癌的有效性和安全性。
■使用PubMed，Embase,WebofScience,还有Cochrane图书馆.包括评估RIAC和全身化疗的比较结果的研究。数据提取和质量评价由两名研究人员独立进行。采用STATA16软件进行统计学分析,计算赔率比(OR)，风险差异(RD)，和95%置信区间(CI)。
■11项研究，共有627名患者，纳入荟萃分析。结果显示，与接受全身化疗的患者相比，接受RIAC的患者部分缓解率（PR）明显更高（OR=2.23，95％CI：1.57，3.15，I2=0％）。此外,RIAC组的并发症发生率较低(OR=0.45,95%CI:0.33,0.63,I2=0%).此外，接受RIAC治疗的患者中位生存时间明显更长.
■这项研究的结果表明，RIAC与较高的部分缓解率有关，改善临床效益，在晚期胰腺癌的治疗中，与全身化疗相比，并发症更少。这些研究结果表明，对于晚期胰腺癌患者，RIAC可能是一种更有效，更安全的治疗选择。
■https://www.crd.约克。AC.英国/普华永道/，标识符CRD42023404637。
■使用PubMed，Embase,WebofScience,还有Cochrane图书馆.包括评估RIAC和全身化疗的比较结果的研究。数据提取和质量评价由两名研究人员独立进行。采用STATA16软件进行统计学分析,计算赔率比(OR)，风险差异(RD)，和95%置信区间(CI)。
■11项研究，共有627名患者，纳入荟萃分析。结果显示，与接受全身化疗的患者相比，接受RIAC的患者部分缓解率（PR）明显更高（OR=2.23，95％CI：1.57，3.15，I2=0％）。此外,RIAC组的并发症发生率较低(OR=0.45,95%CI:0.33,0.63,I2=0%).此外，接受RIAC治疗的患者中位生存时间明显更长.
■这项研究的结果表明，RIAC与较高的部分缓解率有关，改善临床效益，在晚期胰腺癌的治疗中，与全身化疗相比，并发症更少。这些研究结果表明，对于晚期胰腺癌患者，RIAC可能是一种更有效，更安全的治疗选择。
■https://www.crd.约克。AC.英国/普华永道/，标识符CRD42023404637。
